(Q45230598)

English

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

scientific article published on 19 January 2005

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

based on heuristic

inferred from title

randomized controlled trial

1 reference

based on heuristic

inferred from title

Benjamin A. Lipsky

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Uschi Stoutenburgh

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

19 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

240-245

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

A report from the international consensus on diagnosing and treating the infected diabetic foot

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Diagnosis and treatment of diabetic foot infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus - an emerging problem for the management of skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Evidence-based antibiotic therapy of diabetic foot infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Vancomycin therapy of severe staphylococcal infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Antimicrobial resistance trends and outbreak frequency in United States hospitals

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Persistent MRSA bacteremia in a patient with low linezolid levels

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH531

21 January 2018

Identifiers

10.1093/JAC/DKH531

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45230598&oldid=2168188250"